- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00947102
Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer (GEMSTHER)
January 12, 2010 updated by: Blood Transfusion Centre of Slovenia
Observational Study - Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Tubular Carcinoma
Observational study of influence of gemcitabine treatment on serological and immunological status and gene expression profile in patients with pancreatic tubular carcinoma after tumor resection.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lojze Smid, MD
- Email: lojze.smid.jr@mf.uni-lj.si
Study Contact Backup
- Name: Borut Stabuc, MD, PhD
- Phone Number: +386 1 522 22 10
- Email: borut.stabuc@kclj.si
Study Locations
-
-
-
Ljubljana, Slovenia, 1000
- Recruiting
- University Medical Centre Ljubljana; Department for Gastroenterology
-
Contact:
- Lojze Smid, MD
- Email: lojze.smid.jr@mf.uni-lj.si
-
Principal Investigator:
- Borut Stabuc, MD, PhD
-
Contact:
- Borut Stabuc, MD, PhD
- Phone Number: +386 1 522 2210
- Email: borut.stabuc@kclj.si
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients after resection of pancreatic tubular adenocarcinoma
Description
Inclusion Criteria:
- ECOG performance status 0-2 at the time of inclusion
- Following R0 or R1 pancreatic tubular adenocarcinoma resection
Exclusion Criteria:
- Pregnancy
- Serious comorbidity
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Pancreatic tubular adenocarcinoma
Patients with pancreatic tubular adenocarcinoma
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2009
Primary Completion (Anticipated)
December 1, 2011
Study Completion (Anticipated)
December 1, 2011
Study Registration Dates
First Submitted
July 24, 2009
First Submitted That Met QC Criteria
July 24, 2009
First Posted (Estimate)
July 27, 2009
Study Record Updates
Last Update Posted (Estimate)
January 13, 2010
Last Update Submitted That Met QC Criteria
January 12, 2010
Last Verified
July 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Gemcitabine1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Tubular Adenocarcinoma
-
Blood Transfusion Centre of SloveniaUnknownPancreatic Tubular AdenocarcinomaSlovenia
-
The Catholic University of KoreaJanssen Korea, Ltd., KoreaCompletedEarly Gastric Adenocarcinoma | Adenocarcinoma, TubularKorea, Republic of
-
Fudan UniversityUnknownStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Scandion Oncology A/SAlcedis GmbHRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Inoperable Disease | Localized Pancreatic AdenocarcinomaDenmark, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
Clinical Trials on Observation
-
University of MichiganKuwait Foundation for the Advancement of SciencesCompletedGingival RecessionUnited States
-
Istanbul University - Cerrahpasa (IUC)CompletedBrachial Plexus Palsy | Obstetric; InjuryTurkey
-
Centre Hospitalier Régional d'OrléansCompleted
-
Dokuz Eylul UniversityIzmir Katip Celebi UniversityCompleted
-
Istanbul Medeniyet UniversityIstinye University; Ufuk UniversityRecruiting
-
IRCCS San Camillo, Venezia, ItalyUniversità Politecnica delle Marche; University of GenovaUnknown
-
Abant Izzet Baysal UniversityRecruitingMultiple SclerosisTurkey
-
Universidad Autonoma de MadridCompleted
-
Universidad Autonoma de MadridUnknown
-
University of BergenEuropean Society of Intensive Care MedicineCompletedCritical Illness | Old Age; Debility | SurvivalNorway